A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Clinical trial NCT04722172 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04722172
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-21
- Primary completion
- 2027-02-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.